The question that today’s publication addresses with the multicenter, randomized, double-blind, placebo-controlled ORKIDS trial was whether inflammatory disease activity of people living with Lupus was influenced with a “food as medicine” approach of Omega3 Krill Oil supplementation.
The results indicate that Lupus patients have suboptimal omega-3 (measured in red blood cell membranes using the standard omega3 index) which was normalized by one month supplementation with Krill Oil.
AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients.
CLICK FOR ORIGINAL FACEBOOK POST > "Very Interesting. Please Read! Another Lupus Breakthrough!! Wellness Approach to Lupus w/KrillOil Disease activity of #Lupus decreased in a trial of 20sites...
Increasing Omega-3 Index to an optimal level through krill oil supplementation may show benefit for this population and warrants further study.
Dr. Peter Lipsky, AMPEL BioSolutions’ Co-Founder, CEO and Chief Medical Officer, “The ORKIDS clinical trial of Krill Oil supplementation for Lupus was a team effort that documented patients were uniformly omega-3 fatty acid deficient which was reversible with Krill Oil supplementation.